Standardized diagnosis and treatment of immune-related severe cutaneous adverse reactions

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100051052

Enrollment

Unknown

Registered

2021-09-10

Start date

2021-09-10

Completion date

Unknown

Last updated

2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug eruptions

Interventions

immune-related epidermal necrolysis group:corticosteroid with seconde-line treatment

epidermal necrolysis induced by other drugs:corticosteroid with seconde-line treatment

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Aged >= 18 years; clinically diagnosed epidermal necrolysis; provided with informed consent.

Exclusion criteria

Exclusion criteria: Patients with infection-related epidermal necrolysis.

Design outcomes

Primary

Measure	Time frame
mortality rate in acute phase;	—

Countries

China

Contacts

Public ContactJin Hongzhong, He Chunxia

Peking Union Medical College Hospital

592971826@qq.com+86 10 69151500

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026